1 Introduction Messenger RNA (mRNA)-containing lipid nanoparticles (LNPs) have delivered major clinical impact through COVID-19 vaccines [1, 2] and are expanding rapidly toward systemic gene therapy [3, 4]. Beyond intramuscular vaccination, recent efforts have increasingly focused on intravenous dosing for systemic applications [5-7], and conventional LNPs predominantly accumulate in the liver [8, 9].
Minju Lee
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Minju
Contact Minju, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack